Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-121 in Familial Chylomicronemia Syndrome
NCT07176923Phase 1Recruiting
- Sponsor
- CorrectSequence Therapeutics
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- CRISPR-Cas9, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of CS-121 in familial chylomicronemia syndrome (FCS), sponsored by CorrectSequence Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 10 months and Dose-Limiting Toxicities at 10 months. Started Oct 2025; status: recruiting.
02
Drugs
CS-121
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT07176923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176923.